111 (NASDAQ:YI) Trading 3.1% Higher – Should You Buy?

Posted by Defense World Staff on Oct 8th, 2025

111, Inc. Sponsored ADR (NASDAQ:YI – Get Free Report) shares traded up 3.1% during mid-day trading on Tuesday . The stock traded as high as $4.97 and last traded at $4.71. 33,526 shares changed hands during trading, an increase of 26% from the average session volume of 26,575 shares. The stock had previously closed at $4.57.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 111 in a report on Saturday, September 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Read Our Latest Research Report on 111

111 Stock Performance

The company has a fifty day moving average of $6.04 and a two-hundred day moving average of $7.21. The company has a market cap of $40.69 million, a PE ratio of -5.61 and a beta of 0.42.

111 (NASDAQ:YI – Get Free Report) last released its quarterly earnings results on Wednesday, September 17th. The company reported ($0.40) earnings per share for the quarter. The company had revenue of $447.51 million during the quarter.

Institutional Trading of 111

An institutional investor recently bought a new position in 111 stock. Connor Clark & Lunn Investment Management Ltd. bought a new position in 111, Inc. Sponsored ADR (NASDAQ:YI – Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 11,338 shares of the company’s stock, valued at approximately $92,000. Connor Clark & Lunn Investment Management Ltd. owned 0.13% of 111 as of its most recent SEC filing. 21.32% of the stock is owned by institutional investors.

111 Company Profile

(Get Free Report)

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.